A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years

被引：20

作者：

Mateos, Maria-Victoria

Oriol, Albert ^{[2
]}

Martinez, Joaquin ^{[3
]}

Teresa Cibeira, Ma ^{[4
]}

Gutierrez, Norma C. ^{[1
]}

Jose Terol, Maria ^{[5
]}

de Paz, Raquel ^{[6
]}

Garcia-Larana, Jose ^{[7
]}

Bengoechea, Enrique

Martin Garcia-Sancho, Alejandro ^{[8
]}

Martinez, Rafael ^{[9
]}

Palomera, Luis ^{[10
]}

de Arriba, Felipe ^{[11
]}

Gonzalez, Yolanda ^{[12
]}

Hernandez, Jose ^{[13
]}

Sureda, Anna ^{[14
]}

Bello, Jose-Luis ^{[15
]}

Jose Lahuerta, Juan ^{[16
]}

Blade, Joan ^{[17
]}

San-Miguel, Jesus F. ^{[18
]}

机构：

[1] CSIC, USAL, IBMCC, Hosp Univ Salamanca,CIC, Salamanca, Spain

[2] Hosp Badalona Germans Trias & Pujol, Badalona, Spain

[3] Hosp Doce Octubre, Madrid, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Hosp Clin Univ Valencia, Barcelona, Spain

[6] Hosp Univ La Paz, Madrid, Spain

[7] Hosp Ramon & Cajal, E-28034 Madrid, Spain

[8] Hosp Virgen Concha, Zamora, Spain

[9] Hosp Clin San Carlos, Madrid, Spain

[10] Hosp Lozano Blesa, Zaragoza, Spain

[11] Hosp Morales Meseguer, Murcia, Spain

[12] Hosp Josep Trueta, Girona, Spain

[13] Hosp Gen Segovia, Segovia, Spain

[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[15] Hosp Clin Univ Santiago Compostela, Santiago De Compostela, Spain

[16] Hosp 12 Octubre, E-28041 Madrid, Spain

[17] IDIBAPS, Hosp Clin, Barcelona, Spain

[18] Hosp Clin Univ Salamanca, Salamanca, Spain

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.3.3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 4

页数：2

共 50 条

[21] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
Hou, Jian
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Bin Jia
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Wang, Jianxiang
[J]. BLOOD, 2021, 138
[22] Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma
Kim, Min Kyoung
Kim, Kihyun
Yoon, Dok Hyun
Suh, Cheolwon
Lee, Jae Hoon
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Hyo Jung
Kim, Jin Seok
Lee, Jeong-Ok
Eom, Hyeon Seok
Lee, Won Sik
Mun, Yeung-Chul
Do, Young Rok
Kang, Hye Jin
[J]. BLOOD, 2016, 128 (22)
[23] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
Mateos, M., V
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pou
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
[J]. HAEMATOLOGICA, 2018, 103 : 22 - 22
[24] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej J.
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Carson, Robin
Crist, Wendy
Deraedt, William
Nguyen, Marie
Qi, Ming
San-Miguel, Jesus F.
[J]. BLOOD, 2017, 130
[25] Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
Kim, Min Kyoung
Kim, Kihyun
Yoon, Do Hyun
Suh, Cheolwon
Moon, Joon Ho
Lee, Yoo Jin
Lee, Jae Hoon
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Hyo Jung
Bae, Sung Hwa
Kim, Jin Seok
Lee, Jeong-Ok
Eom, Hyeon Seok
Lee, Won-Sik
Kang, Hye Jin
Mun, Yeung-Chul
Do, Young Rok
Hyun, Myung Soo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E70
[26] Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma
Yeh, Yating
Chambers, James
Gaugris, Sabine
Jansen, Jeroen
[J]. BLOOD, 2008, 112 (11) : 825 - 825
[27] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Kobos, Rachel
San-Miguel, Jesus
[J]. BLOOD, 2019, 134
[28] The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
Garrison, Louis P., Jr.
Wang, Si-Tien
Huang, Hui
Ba-Mancini, Abbie
Shi, Hongliang
Chen, Kristina
Korves, Caroline
Dhawan, Ravinder
Cakana, Andrew
van de Velde, Helgi
Corzo, Deyanira
Duh, Mei Sheng
[J]. ONCOLOGIST, 2013, 18 (01): : 27 - 36
[29] Bortezomib plus melphalan and prednisone (VMP) in elderly untreated patients with multiple myeloma:: Prognostic factors influencing time to progression
Mateos, M.-V. M.
Hernandez, J.-M.
Hemandez, M.-T.
Gutierrez, N.-C.
Palomera, L.
Fuertes, M.
Garcia, P.
Lahuerta, J. J.
De la Rubia, J.
Terol, M. J.
Sureda, A.
Bargay, J.
Ribas, P.
De Arriba, E.
Alegre, A.
Oriol, A.
Carrera, D.
Garcia-Larana, J.
Garcia-Sanz, R.
Bladé, J.
Prosper, F.
Esseltine, D.-L.
Van de Velde, H.
San-Miguel, J.-F.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 148 - 149
[30] Prognostic factors in advanced multiple myeloma patients treated with the association of bortezomib, melphalan, prednisone and thalidomide (VMPT)
Palumbo, A.
Gay, F.
Ambrosini, M. T.
Benevolo, G.
Pregno, F.
Pescosta, N.
Callea, V
Cangialosi, C.
Caravita, T.
Morabito, F.
Musto, P.
Larocca, A.
Caltagirone, S.
Avonto, I
Cavallo, F.
Boccadoro, M.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 140 - 140

← 1 2 3 4 5 →